Public Employees Retirement System of Ohio Invests $353,000 in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Public Employees Retirement System of Ohio acquired a new position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 37,461 shares of the biopharmaceutical company's stock, valued at approximately $353,000. Public Employees Retirement System of Ohio owned approximately 0.08% of Theravance Biopharma at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Aquatic Capital Management LLC bought a new position in Theravance Biopharma in the 4th quarter worth $25,000. KLP Kapitalforvaltning AS purchased a new position in shares of Theravance Biopharma in the fourth quarter valued at about $69,000. Teacher Retirement System of Texas purchased a new position in shares of Theravance Biopharma in the fourth quarter valued at about $103,000. ClearAlpha Technologies LP bought a new position in shares of Theravance Biopharma in the fourth quarter worth about $109,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Theravance Biopharma by 142.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 12,670 shares of the biopharmaceutical company's stock worth $119,000 after purchasing an additional 7,452 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 24,000 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $11.00, for a total transaction of $264,000.00. Following the sale, the senior vice president now directly owns 336,918 shares of the company's stock, valued at $3,706,098. This represents a 6.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

TBPH has been the topic of several recent analyst reports. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a report on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $11.33.

Theravance Biopharma Stock Up 4.5%

TBPH stock traded up $0.48 during mid-day trading on Friday, hitting $11.25. The company had a trading volume of 295,003 shares, compared to its average volume of 276,302. The company has a 50-day moving average price of $9.35 and a 200 day moving average price of $9.39. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $11.82. The company has a market capitalization of $562.51 million, a price-to-earnings ratio of -11.14 and a beta of -0.09.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The firm had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. As a group, analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.